Last updated on November 2017

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma


Brief description of study

A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3Kd Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma

Detailed Study Description

The purpose of this study is to compare INCB050465 with idelalisib for objective response rate (ORR) in subjects with relapsed or refractory follicular lymphoma (FL).

Clinical Study Identifier: TX14253

Contact Investigators or Research Sites near you

Start Over
Sorry. There are no research Sites conducting this study in the radius provided. ( View all Sites )